Novartis buying IFM inflammasome unit less than a year after launch

Novartis will pay $310 million up front to acquire IFM Tre and its trio of NLRP3 antagonists. Shareholders of the inflammatory disease subsidiary are also eligible for up to $1.3 billion in milestones.

IFM Therapeutics LLC (Boston, Mass.) launched IFM Tre

Read the full 401 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE